[{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"TLR3","graph1":"Oncology","graph2":"Phase II","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"8","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"},{"orgOrder":0,"company":"Roswell Park Comprehensive Cancer Center","sponsor":"Generate Biomedicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"CAR T-Cell Therapy","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Roswell Park Comprehensive Cancer Center","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Roswell Park Comprehensive Cancer Center \/ Roswell Park Comprehensive Cancer Center"}]

Find Clinical Drug Pipeline Developments & Deals by Roswell Park Comprehensive Cancer Center

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The collaboration aims to discover and develop chimeric antigen receptor (CAR) T-cell therapies, and armoring technologies, for up to three oncology targets, including in ovarian cancer and other solid tumors.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          November 01, 2023

                          Lead Product(s) : CAR T-Cell Therapy

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Recipient : Generate Biomedicines

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Ampligen is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen has demonstrated in the clinic the potential for standalone efficacy in a number of solid tumors.

                          Brand Name : Ampligen

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          November 14, 2022

                          Lead Product(s) : Rintatolimod,Interferon Alfa-2B,Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Aim ImmunoTech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Ampligen (rintatolimod) is AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system.

                          Brand Name : Ampligen

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          August 30, 2022

                          Lead Product(s) : Rintatolimod,Interferon Alfa-2B,Celecoxib

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Aim ImmunoTech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The data, from a small number of subjects, is extremely impressive for four out of six Ampligen plus pembrolizumab patients; three demonstrated disease stabilization and one showed a significant and dramatic rapid destruction of the tumor and metastasis.

                          Brand Name : Ampligen

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 11, 2022

                          Lead Product(s) : Rintatolimod,Celecoxib,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Recipient : Aim ImmunoTech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Primary endpoint of the study was met for Ampligen (rintatolimod), selective TLR3 ligand, evidenced by increased CD8a expression post-treatment (p=0.046), as a component of treatment for colorectal cancer metastatic to the liver.

                          Brand Name : Ampligen

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 11, 2022

                          Lead Product(s) : Rintatolimod,Celecoxib,Recombinant Interferon Alfa-2b

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Recipient : Aim ImmunoTech

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank